Ryvu Therapeutics SA
WSE:RVU
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
R
|
Ryvu Therapeutics SA
WSE:RVU
|
PL |
|
MSP Recovery Inc
NASDAQ:LIFW
|
US |
|
Sandmartin International Holdings Ltd
HKEX:482
|
HK |
|
Hangzhou Onechance Tech Corp
SZSE:300792
|
CN |
|
Inmobiliaria del Sur SA
MAD:ISUR
|
ES |
|
P
|
Pengana Capital Group Ltd
ASX:PCG
|
AU |
|
D
|
Dio Corp
KOSDAQ:039840
|
KR |
Ryvu Therapeutics SA
Ryvu Therapeutics SA engages in the provision of products and solutions for the pharmaceutical and biotechnology industry. The company is headquartered in Krakow, Woj. Malopolskie and currently employs 186 full-time employees. The company went IPO on 2011-07-14. The firm is active in the pharmaceutical and biotechnology fields. The company operates through two business segments. The Innovative segment develops new drugs mainly for oncology and central nervous system diseases. The Services segment is engaged in the research and development activities, such as introducing substances on the market, client service and reducing the risk. The Company’s portfolio encompasses projects, including kinesis inhibitors platform, the platform of the metabolism for the cancer and epigenetic, among others. Ryvu Therapeutics SA is active in the domestic market and internationally, such as in the United States. The company operates through unit Ardigen SA and SORS Holdings Ltd.
Ryvu Therapeutics SA engages in the provision of products and solutions for the pharmaceutical and biotechnology industry. The company is headquartered in Krakow, Woj. Malopolskie and currently employs 186 full-time employees. The company went IPO on 2011-07-14. The firm is active in the pharmaceutical and biotechnology fields. The company operates through two business segments. The Innovative segment develops new drugs mainly for oncology and central nervous system diseases. The Services segment is engaged in the research and development activities, such as introducing substances on the market, client service and reducing the risk. The Company’s portfolio encompasses projects, including kinesis inhibitors platform, the platform of the metabolism for the cancer and epigenetic, among others. Ryvu Therapeutics SA is active in the domestic market and internationally, such as in the United States. The company operates through unit Ardigen SA and SORS Holdings Ltd.
